
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
Relief is finally at hand for patients with leukemia or lymphoma who must undergo extremely high dose chemotherapy and radiation to prep for bone marrow transplant. A new agent will reduce their chances of developing mucositis-severe ulceration of the oral mucosa caused by the cancer treatments themselves.